AI in trials Altis Labs focuses on AI-driven imaging prognostics (IPRO) to accelerate clinical trials, presenting a sales opportunity to CROs, biopharma sponsors, and trial sites seeking faster data-driven trial designs and improved outcomes.

Large cancer imaging Boasted among the world’s largest cancer imaging databases with longitudinal clinical context, enabling organizations to leverage IPRO models to predict outcomes beyond tumor size, appealing to pharma companies prioritizing robust prognostic insights.

Strategic partnerships Active collaboration track record with University Health Network and participation in high-profile oncology events (ISPOR, CBCS, ASCO) signals readiness for co-development and external control arm offerings, presenting partner-driven sales avenues.

Commercial traction Recent awards and multi-year collaborations, plus an annual-revenue range in the low millions and a focused team, indicate a scalable, niche solution with room to upsell into larger pharma pipelines and larger CRO engagements.

Tech and security backing Tech stack and cloud-based infrastructure (AWS, Microsoft Azure, data analytics tools) support scalable, compliant deployment for pharma clients, suggesting assurance points around data security, integration, and enterprise-ready deployment.